Wyniki wyszukiwania - AGRO

1

Expression of c-erbB-2 oncoprotein in proliferative and hyperplastic human endometrium

100%

Semczuk A., Miturski R., Tomaszewski J., Postawski K., Kotarski J., Jakowicki J.

Cellular and Molecular Biology Letters

|

1998

|

tom 03

|

nr 2

2

Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik

Effect of selenium on breast cancer in women - part I

88%

Sygit K., Sieja K., Sygit M., Pasierbiak K.

Health Problems of Civilization

|

2018

|

tom 12

|

nr 2

Background. Breast cancer is the most common malignant tumour in women in Poland. To reduce the risk of breast cancer, appropriate prevention is necessary. Numerous studies conducted over many years in Poland and throughout the world have demonstrated a significant effect of selenium on prevention of disease, including breast cancer in women. The following paper aims to present the literature on effects of selenium (Se) on prevention of breast cancer in women. Material and methods. Based on national and international literature, the paper presents information on the role of selenium (Se) in prevention of breast cancer in women. Results. Numerous studies conducted in research centres in Poland and abroad have shown that female patients with breast cancer and individuals with gastrointestinal cancer have significantly lower selenium concentration in their blood serum and whole blood, as well as significantly lower GSH - Px activity in plasma and red blood cells, compared to healthy women. Low selenium concentration may indicate an increased risk of breast cancer. Selenium is an essential co-factor in the production of antioxidant enzymes and may affect the development of cancer. Clinical trials which assessed selenium content in food showed that its supplementation reduced cancer mortality. Conclusions. Results of numerous national and prospective international studies indicate that low selenium intake and/or concentration in serum/plasma/nails is a high-risk marker of the majority of cancers, including breast cancer in women.

3

Expression of genes modulated by epigallocatechin-3-gallate in breast cancer cells

88%

Bogacz A., Wolek M., Juskowiak B., Karasiewicz M., Kaminski A., Uzar I., Polaszewska A., Kostrzewa Z., Czerny B.

Herba Polonica

|

2018

|

tom 64

|

nr 3

Breast cancer is the most common malignant cancer among women. Both drug resistance and metastasis are major problems in the treatment of breast cancer. Therefore, adjuvant therapy may improve patients’ survival and affect their quality of life. It is suggested that epigallocatechin gallate (EGCG) which is well known for its chemopreventive activity and acts on numerous molecular targets may inhibit the growth and metastasis of some cancers. Hence, discovering the metastatic molecular mechanisms for breast cancer may be useful for therapy.The aim of the study was to determine the effect of EGGC on the mRNA expression level of genes such as ZEB1, ABCB1, MDM2, TWIST1 and PTEN in MCF-7 breast cancer cells. MCF7/DOX were cultured in the presence of 0.2 μM DOX and EGCG (20-50 μM). The mRNA expression level was determined by real-time quantitative PCR using RealTime ready Custom Panel 96 kit. Our results showed an important increase (about 2-fold for 20 μM EGCG + 0.2 μM DOX and 2.5-fold for 50 μM EGCG + 0.2 μM DOX, p<0.05) in ZEB1 expression levels. In case of ABCB1 gene lack of influence on the mRNA level was observed (p>0.05). We also observed significant decrease of ZEB1 expression in MCF7 cells with 20 μM and 50 μM EGCG (p<0.05). In addition, EGCG (20 μM) caused an increase of MDM2 and PTEN mRNA levels in almost 100% (p<0.05) and 40% (p>0.05), respectively. Lack of the influence of EGCG was noted for the TWIST1 gene expression. In case of MCF7/DOX we showed an increase of mRNA level of PTEN gene about 50% (p<0.05). These results suggest that EGCG may be potentially used in adjuvant therapy in the breast cancer treatment.

4

Analysis of microsatellite instability and loss of heterozygosity in breast cancer with the use of a well characterized multiplex system

88%

Powierska-Czarny J., Miscicka-Sliwka D., Czarny J., Grzybowski T., Wozniak M., Drewa G., Czechowicz W., Sir J.

Acta Biochimica Polonica

|

2003

|

tom 50

|

nr 4

Analysis of microsatellite instability (MI) and loss of heterozygosity (LOH) is recommended for screening patients with sporadic and hereditary malignancies. This study shows an application of a fluorescent hexaplex PCR system for microsatellite typing on A.L.F. DNA Sequencer (Pharmacia Biotech). This technique detects changes in microsatellites providing a time-efficient, reliable and accurate method for MI and LOH analyses. The Fragment Manager software was used for automated size calculation and quantitation of DNA fragments, enabling rapid and precise measurement of allelic ratios. We examined 70 breast cancer and 70 control DNA specimens, classified all the patterns of microsatellite alterations, and set up MI and LOH assessment criteria for the automated multiplex fluorescent method.

5

Elevated plasma levels of tissue factor as a valuable diagnostic biomarker with relevant efficacy for prediction of breast cancer morbidity

75%

Zarychta E., Rhone P., Bielawski K., Rosc D., Szot K., Zdunska M., Ruszkowska-Ciastek B.

Journal of Physiology and Pharmacology

|

2018

|

tom 69

|

nr 6

6

Hormonal contraceptives and hormone replacement therapy as a possible factor of breast cancer

75%

Predna L., Habanova M., Slavikova E., Wyka J.

Roczniki Państwowego Zakładu Higieny

|

2015

|

tom 66

|

nr 3

Background. Breast cancer is a disease with an increasing incidence, and it originates from several factors. Risk factors of this disease represent a diverse group of parameters, which also include hormonal influences. Objective. The aim of the present study was to determine if there is a relationship between hormonal contraceptives and hormone replacement therapy in patients with diagnosed most common types of breast cancer taking into account the age at which the disease was diagnosed in selected sonographic clinic in the district of Nitra, Slovak Republic. Material and Methods. As a part of an ongoing retrospective study from 2005, a cohort of 300 randomly selected patients aged 25-87 years with diagnosed breast cancer have been monitored in 2012. The age at which breast cancer was diagnosed, and relationship to hormone therapy were analysed based on medical documentation. Results. Among 300 randomly selected patients with a confirmed diagnosis of breast cancer the group at the age of 40-59 was the most numerous (mean age was 53.06±11.25 years). The mean age of 45 patients who were given hormonal contraceptives (HC) was 46.44±7.34 years, whereas the mean age of 82 patients who were subjected to hormone replacement therapy (HRT) was 53.63±6.67 years. In women who took hormonal treatment, breast cancer was diagnosed at the mean age of 50.60±7.56 years, while women who never took HRT or HC, were diagnosed around the age of 53.92±12.35 years. The most common types of cancer were the infiltrating ductal carcinoma and lobular carcinoma. From all patients, the relapse occurred among 14 of them, about 4.86 years later. Only 2 patients had breast cancer on both diagnosed breast. After a surgery, the cancer was observed in 7 patients. The positive family history was confirmed with 34 patients. Conclusions. Nowadays, the breast cancer treatment, especially at early stages, is successful, however, the malignant breast neoplasm remains the most common oncological disease causing the death amongst women. In the assessment of the impact of HC and HRT on breast cancer, it is not possible to provide a clear conclusion, because their influence on the tumour is difficult to verify.

7

The breast-conserving surgery of women with breast cancer in Podlaskie voivodship (Poland). Population study

75%

Maslach D., Krzyzak M., Szpak A., Bojar I., Bielska-Lasota M., Owoc A.

Annals of Agricultural and Environmental Medicine

|

2013

|

tom 20

|

nr 2

Introduction. The results of breast cancer treatment depend mainly on better detection in mammography screening and, consequently, a higher proportion of women with early stage of the disease. They depend also on a better access to health care services and the effectiveness of oncological treatment. One of the methods of breast cancer control is a breastconserving surgery. With a proper patients’ classification for the treatment, the results of the breast-conserving surgery do not differ in relation to mastectomy. That’s why, the availability of breast-conserving surgical methods is particularly important, especially in a population in which a population screening is conducted. Objective. The analysis of the selected aspects of the breast cancer treatment’s standard in Podlaskie Voivodeship. Patients and methods. In years 2001–2002, 709 cases of women with breast cancer were reported to the Voivodeship Cancer Registry in Bialystok. 659 women were diagnosed with a primary invasive breast cancer. Based on a cohort of 499 women treated with radical methods the following indicators, recommended by WHO for the evaluation of the breastconserving surgery’s availability, were calculated: a percentage of patients with whom breast-conserving surgery was used, a proportion of breast cancer cases receiving post-operative breast radiotherapy after breast-conserving surgery and a proportion of breast-conserving surgery in pT1 cases. Results. The breast-conserving surgery has been used much less frequently in Podlaskie Voivodeship than in Western Europe, but more frequently than in Poland in general. Conclusion. It should be aimed to provide a surgical treatment with the use of breast-conserving surgical methods to the highest possible percentage of patients. The increase of the percentage of patients treated with breast-conserving surgery methods can be a result of an effective screening realisation.

8

Genetic predisposition to breast and/or ovarian cancer – focus on the candidate BARD1 gene

75%

Klonowska K., Ratajska M., Wojciechowska M., Kozlowski P.

BioTechnologia. Journal of Biotechnology Computational Biology and Bionanotechnology

|

2014

|

tom 95

|

nr 3

9

The importance of preoperative elevated serum levels of CEA and CA15-3 in patients with breast cancer in predicting its histological type

75%

Agrawal A. K., Jelen M., Rudnicki J., Grzebieniak Z., Zysko D., Kielan W., Slonina J., Marek G.

Folia Histochemica et Cytobiologica

|

2010

|

tom 48

|

nr 1

26-29

10

Breast self-examination as a method for early detection of breast cancer based on literature review

75%

Marszalek A., Walaszek R.

Health Problems of Civilization

|

2015

|

tom 09

|

nr 4

11

Increased serum level of membrane type 1-matrix metalloproteinase [MT1-MMP-MMP-14] in patients with breast cancer

75%

Laudanski P., Swiatecka J., Kozlowski L., Lesniewska M., Wojtukiewicz M., Wolczynski S.

Folia Histochemica et Cytobiologica

|

2010

|

tom 48

|

nr 1

101-103

12

Correlation between scharf - bloom index and stromal modifications in the breast cancer

75%

Raica M.

Folia Morphologica

|

1988

|

tom 47

|

nr 1-4

13

Immune reaction to breast cancer: for better or for worse?

75%

Ogmundsdottir H. M.

Archivum Immunologiae et Therapiae Experimentalis. Supplement

|

2001

|

tom 49

|

nr 2

75-81

14

Reduced expression of AURKA in peripheral blood of breast cancer patients

75%

Goh L. P. W., See E. U. H., Chua K. H., Lee P.-C.

BioTechnologia. Journal of Biotechnology Computational Biology and Bionanotechnology

|

2018

|

tom 99

|

nr 1

15

Dendritic cells in peripheral blood of patients with breast and lung cancer - a pilot study

75%

Wojas K., Tabarkiewicz J., Jankiewicz M., Rolinski J.

Folia Histochemica et Cytobiologica

|

2004

|

tom 42

|

nr 1

16

Correlation between the occurrence of Ki-67 antigen and clinical parameters in human breast carcinoma

75%

Mirecka J., Korabiowska M., Schauer A.

Folia Histochemica et Cytobiologica

|

1993

|

tom 31

|

nr 2

17

A single nucleotide polymorphism in the 5'untranslated region of RAD51 in breast cancer

75%

Blasiak J., Przybylowska K., Czechowska A., Zadrozny M., Rykala J., Kolacinska A., Morawiec Z., Drzewoski J.

Cellular and Molecular Biology Letters

|

2002

|

tom 07

|

nr Suppl.

18

The effect of phytoestrogens on the reproductive tract

75%

Slomczynska M.

Polish Journal of Veterinary Sciences

|

2004

|

tom 07

|

nr 3

Environmental estrogens may be derived from plants (phytoestrogens), pharmaceuticals or synthetic compounds. They exert estrogenic and/or potentially antiestrogenic effects on farm animals, wildlife and humans. Exposure to these compounds results in some abnormalities in the reproductive tract, changes in the estrous cycle, and possibly protection against the development of hormone- dependent cancer. The data obtained from animal studies suggest that the timing of exposure to phytoestrogens is important, and neonatal exposure causes the most pronounced effects.

19

Inhibition of cathepsin B acivity in human breast cancer tissue by cysteine peptidase inhibitor isolated from human placenta: immunohistochemical and biochemical studies

75%

Saleh Y., Siewinski M., Sebzda T., Jelen M., Ziolkowski P., Gutowicz J., Grybos M., Pawelec M.

Folia Histochemica et Cytobiologica

|

2003

|

tom 41

|

nr 3

20

Abnormal FHIT gene transcript and c-myc and c-erbB2 amplification in breast cancer

75%

Kowara R., Golebiowski F., Chrzan P., Skokowski J., Karmolinski A., Pawelczyk T.

Acta Biochimica Polonica

|

2002

|

tom 49

|

nr 2

Searching for ways to improve the characterization of breast cancer we examined the relationship between the status of the FHIT gene transcript and amplification of c-myc and the c-erbB2 oncogene. Abnormal FHIT transcript was detected in 32 of 79 cancers examined. The presence of Fhit protein estimated by Western blots was evident only in cancers exhibiting a normal-sized FHIT transcript. This indicates that abnormal FHIT transcripts observed in our study did not encode any Fhit protein or the amount of such protein was very low. There was no association between the presence of aberrant FHIT gene transcript with age, tumor size, estrogen and progesterone receptor status, local metastases and histological grading. However, the abnormalities in FHIT gene transcripts were observed with different frequency depending on the histopathological type of the tumor. The aberrant FHIT transcript was detected in 60% of lobular cancers and only in 28% of ductal cancers. Analyzing the occurrence of c-myc and c-erbB2 amplification and the presence of aberrant FHIT gene transcripts we found that the aberrant FHIT transcript more frequently occurred in tissues with c-myc amplification. There was a significant (P < 0.05) correlation between the occurrence of the aberrant FHIT gene transcript with accompanying c-myc amplification and positive lymph node status. However, in order to evaluate the predictive value of these findings in breast cancer, an extended clinical follow up will be necessary.

Ograniczanie wyników